Scinai ends PC111 arrangements, refocuses capital on NanoAb and CDMO
Scinai Immunotherapeutics said it has concluded its PinCell option and license arrangements, concentrating resources on its NanoAb platform and CDMO commercial execution without taking on additional PC111 funding commitments.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.